Pediatric Functional ConstipationNCT05787093
ROLE OF PELVIC ULTRASOUND IN THE TREATMENT MONITORING OF CHILDREN WITH CHRONIC Idiopathic Constipation
An observational study of Pediatric Functional Constipation, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
Trial summary
Constipation is a frequently encountered problem in childhood, with a prevalence ranging between 1 and 30%. Several studies have proposed pelvic ultrasound, (simple, non-invasive and reproducible) both to define the presence of megarectum, and to follow the answer to treatment, but the real utility remains to be… Read more about this study
- Who is it for?
- Ages 4 to 18 years
- Conditions the study is for
- Pediatric Functional Constipation
- What is being tested?
- transabdominal rectal ultrasound
- Type of treatment
- Medical device
- How many people
- 123 participants
- Where
- 1 siteItaly
- Study dates
- 1 Sep 2022to 1 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: pediatric patients aged 4 years and older with chronic functional constipation
Who may be able to join
- pediatric patients (between 4 and 18 years of age) accessing the services outpatient or pediatric first aid for constipation (according to Rome IV criteria)
- rectal diameter superior to 3 cm on the transabdominal echo
- presence of informed consent to participation in the study by minors and children parents/legal guardians
Who cannot join
- age under 4 years;
- previous anorectal surgery;
- suspicion of anamnestic and/or clinical examination of an organic cause of constipation.rectal diameter \< 3 cm on the transabdominal echo
- absence of informed consent to participation in the study by minors and parents/guardians legal.
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Policlinico universitario agostino gemelli IRCCS
Roma, 00168
valentina giorgio, 0630155940, valentina.giorgio@policlinicogemelli.it
About this study
Constipation is a frequently encountered problem in childhood, with a prevalence ranging between 1 and 30%. Several studies have proposed pelvic ultrasound, (simple, non-invasive and reproducible) both to define the presence of megarectum, and to follow the answer to treatment, but the real utility remains to be defined, especially in the follow-up.The primary aim of the study is to evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment.
Read the detailed description
Constipation is a frequently encountered problem in childhood, with a prevalence ranging between 1 and 30%. From an etiological point of view, we distinguish the form functional/idiopathic (≈ 95%), defined according to the Rome IV Criteria, and shape secondary (≈ 5%). Fecal retention in chronic constipation often causes a dilatation of the rectum (megarectum), the extent of which affects the response to treatment. Several studies have proposed pelvic ultrasound, (simple, non-invasive and reproducible) both to define the presence of megarectum, and to follow the answer to treatment, but the real utility remains to be defined, especially in the follow-up. In case of persistence of megarectum and intractable constipation despite treatment conventional, anorectal manometry should be considered, aiming to identify conditions of colonic dysmotility. The latter could be excluded adopted unconventional biofeedback treatments, the effectiveness of which, however, is still little standardized.
Primary objective: To evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment. Secondary objectives: 1) to define the prevalence of chronic idiopathic intractable constipation in our center; 2) Document whether the biofeedback treatment is effective in terms of rectal diameter reduction, ultrasound documented, and response clinical outcome, assessed by means of a validated questionnaire, in the subclass of patients with constipation chronic idiopathic resistant to conventional treatment. Inclusion criteria: pediatric patients (between 4 and 18 years of age) accessing services outpatient or pediatric first aid for constipation (according to Rome IV criteria) Exclusion criteria: age \< 4 years; previous anorectal surgery; suspicion of anamnestic and/or clinical examination of an organic cause of constipation.
123 pediatric patients with chronic idiopathic constipation. The characteristics of the patients included in the study will be initially analysed (gender, age, anthropometric parameters), ultrasound data and the degree of severity of disease through a descriptive analysis. Mean and standard deviation or median e interquartile range will be used to summarize the quantitative type variables, upon verification of the assumption of normality with the Shapiro-Wilk test, while absolute frequency and percentage will be used for the qualitative variables. The data ultrasound and clinical scores will be analyzed at each time point and will be calculated the change from the previous time point. Statistically significant changes will be evaluated through the Student's t-test (quantitative variables normally distributed), the Mann-Whitney test (quantitative variables not normally distributed) or the Chi-square test (qualitative variables). Spearman's correlation index will come calculated to evaluate the concordance of the aforementioned variations. An effect model mixed for repeated measures will be used to evaluate the clinical improvement of patients over time (t1, t2, t3). Clinical improvement is indicated as a reduction in the diameter of the rectum identified by ultrasound analysis and a decrease of the severity score of the disease identified through the validated questionnaire. In the patients undergoing the biofeedback cycle will be evaluated for clinical improvement through the comparison between the ultrasound data and the scores collected before the start of the cycle with data collected at the end of the cycle using Student's t-test (quantitative variables normally distributed), the Mann-Whitney test (quantitative variables not normally distributed) or the Chi-square test (qualitative variables). Within the scope of the entire study the statistical significance is identified at a level of 5%. The prevalence estimates will be accompanied by the relative 95% confidence intervals.
Statistical analysis will be performed with R software version 4.1.1.
- Conditions
- Pediatric Functional Constipation
- Being tested
- transabdominal rectal ultrasound
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transabdominal rectal ultrasoundDevice
transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
| Study group | Role | What they receive |
|---|---|---|
| pediatric patients accessing for constipation with rectal diameter >3 cm | Not described Receives: Device: transabdominal rectal ultrasound | |
| pediatric patients accessing for constipation with rectal diameter <3 cm | Not described Receives: Device: transabdominal rectal ultrasound |
What is being measured
The primary outcome is the main question the study is designed to answer.
primary outcome
Evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment.
Measured: day one
primary outcome
Evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment.
Measured: month 2
primary outcome
Evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment.
Measured: month 4
Secondary outcomes (1)
Secondary outcome
define the prevalence of chronic idiopathic intractable constipation in our center; Document whether the biofeedback treatment is effective in terms of rectal diameter reduction, ultrasound documented, and response clinical outcome, assessed by means of a validated questionnaire, in the subclass of patients with constipation chronic idiopathic resistant to conventional treatment.
Measured: day one
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2023
- Study start1 Sep 2022
- Primary completion1 Mar 2023
- Study completion1 Sep 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pediatric Functional ConstipationStudies of the same condition, open and under way.
- More trials run by Fondazione Policlinico Universitario Agostino Gemelli IRCCSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 123 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Giorgio Valentina, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05787093
- Sponsor's protocol ID
- PEDCONSTIPATION21
- Status last verified
- Mar 2023
- First submitted
- 3 Mar 2023
- Last updated
- 28 Mar 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 28 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ROLE OF PELVIC ULTRASOUND IN THE TREATMENT MONITORING OF CHILDREN WITH CHRONIC Idiopathic Constipation
- ClinicalTrials.gov ID
- NCT05787093
- Acronym / sponsor ID
- PEDCONSTIPATION21
- Conditions
- Pediatric Functional Constipation
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 123 participants (estimated)
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 1 Mar 2023 (actual)
- Study completion
- 1 Sep 2024 (estimated)
- First posted
- 28 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Constipation is a frequently encountered problem in childhood, with a prevalence ranging between 1 and 30%. Several studies have proposed pelvic ultrasound, (simple, non-invasive and reproducible) both to define the presence of megarectum, and to follow the answer to treatment, but the real utility remains to be defined, especially in the follow-up.The primary aim of the study is to evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment.
Detailed description
Constipation is a frequently encountered problem in childhood, with a prevalence ranging between 1 and 30%. From an etiological point of view, we distinguish the form functional/idiopathic (≈ 95%), defined according to the Rome IV Criteria, and shape secondary (≈ 5%). Fecal retention in chronic constipation often causes a dilatation of the rectum (megarectum), the extent of which affects the response to treatment. Several studies have proposed pelvic ultrasound, (simple, non-invasive and reproducible) both to define the presence of megarectum, and to follow the answer to treatment, but the real utility remains to be defined, especially in the follow-up. In case of persistence of megarectum and intractable constipation despite treatment conventional, anorectal manometry should be considered, aiming to identify conditions of colonic dysmotility. The latter could be excluded adopted unconventional biofeedback treatments, the effectiveness of which, however, is still little standardized.
Primary objective: To evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment. Secondary objectives: 1) to define the prevalence of chronic idiopathic intractable constipation in our center; 2) Document whether the biofeedback treatment is effective in terms of rectal diameter reduction, ultrasound documented, and response clinical outcome, assessed by means of a validated questionnaire, in the subclass of patients with constipation chronic idiopathic resistant to conventional treatment. Inclusion criteria: pediatric patients (between 4 and 18 years of age) accessing services outpatient or pediatric first aid for constipation (according to Rome IV criteria) Exclusion criteria: age \< 4 years; previous anorectal surgery; suspicion of anamnestic and/or clinical examination of an organic cause of constipation.
123 pediatric patients with chronic idiopathic constipation. The characteristics of the patients included in the study will be initially analysed (gender, age, anthropometric parameters), ultrasound data and the degree of severity of disease through a descriptive analysis. Mean and standard deviation or median e interquartile range will be used to summarize the quantitative type variables, upon verification of the assumption of normality with the Shapiro-Wilk test, while absolute frequency and percentage will be used for the qualitative variables. The data ultrasound and clinical scores will be analyzed at each time point and will be calculated the change from the previous time point. Statistically significant changes will be evaluated through the Student's t-test (quantitative variables normally distributed), the Mann-Whitney test (quantitative variables not normally distributed) or the Chi-square test (qualitative variables). Spearman's correlation index will come calculated to evaluate the concordance of the aforementioned variations. An effect model mixed for repeated measures will be used to evaluate the clinical improvement of patients over time (t1, t2, t3). Clinical improvement is indicated as a reduction in the diameter of the rectum identified by ultrasound analysis and a decrease of the severity score of the disease identified through the validated questionnaire. In the patients undergoing the biofeedback cycle will be evaluated for clinical improvement through the comparison between the ultrasound data and the scores collected before the start of the cycle with data collected at the end of the cycle using Student's t-test (quantitative variables normally distributed), the Mann-Whitney test (quantitative variables not normally distributed) or the Chi-square test (qualitative variables). Within the scope of the entire study the statistical significance is identified at a level of 5%. The prevalence estimates will be accompanied by the relative 95% confidence intervals.
Statistical analysis will be performed with R software version 4.1.1.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| pediatric patients accessing for constipation with rectal diameter >3 cm | – | Device: transabdominal rectal ultrasound |
| pediatric patients accessing for constipation with rectal diameter <3 cm | – | Device: transabdominal rectal ultrasound |
Who may qualify
- Ages
- 4 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- pediatric patients aged 4 years and older with chronic functional constipation
Key inclusion criteria (3 listed)
- pediatric patients (between 4 and 18 years of age) accessing the services outpatient or pediatric first aid for constipation (according to Rome IV criteria)
- rectal diameter superior to 3 cm on the transabdominal echo
- presence of informed consent to participation in the study by minors and children parents/legal guardians
Key exclusion criteria (4 listed)
- age under 4 years;
- previous anorectal surgery;
- suspicion of anamnestic and/or clinical examination of an organic cause of constipation.rectal diameter \< 3 cm on the transabdominal echo
- absence of informed consent to participation in the study by minors and parents/guardians legal.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transabdominal rectal ultrasoundtransabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol | Device | pediatric patients accessing for constipation with rectal diameter <3 cm, pediatric patients accessing for constipation with rectal diameter >3 cm |
Primary outcome
primary outcome
Time frame: day one
Evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment.
primary outcome
Time frame: month 2
Evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment.
primary outcome
Time frame: month 4
Evaluate whether, in the conventional treatment of functional constipation of the child, the variations of the rectal diameter, measured through the use of the pelvic ultrasound, are a good marker of disease severity and efficacy of the treatment.
1 secondary outcome
Secondary outcome
Time frame: day one
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Mar 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Pediatric Functional Constipation
Active, not recruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
Functional Constipation (FC)
Not yet recruiting
Comparison of a New Non-invasive Device With the Invasive Gold-standard Investigation to Assess Function of the Large Bowel in Children
Bowel Dysfunction, Dysmotility
Not yet recruiting
Target Physiotherapy Versus Exercise Support Intervention for Bladder-bowel Dysfunction in Adolescents With Obesity
Bladder-Bowel Dysfunction, Obesity & Overweight
Recruiting
Improvement of Understanding of Pediatric Sacral Neuromodulation: Therapeutic Strategies and Outcome Variables
Gastrointestinal Motility Disorders in Children, Hirschsprung Disease
Enrolling by invitationObservational study
Study of Transition in Real-life Experiences Affecting Micturition and Well-being in Adolescent Years
Lower Urinary Tract Symptoms (LUTS), Transition Care
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pediatric Functional Constipation, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Valentina giorgio (0630155940, valentina.giorgio@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
primary outcome (time frame: day one). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2023.